Collaboration with regulatory, industry, and academic partners will support and accelerate the development and validation of workflows to conduct virtual bioequivalence studies
![Simulations Plus Hosts First-of-its-Kind Virtual Summer Camp for Students and Professors](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Hosts First-of-its-Kind Virtual Summer Camp for Students and Professors
Immersive activities helped attendees globally learn and apply best practices for PBPK modeling
![Simulations Plus Chief Science Officer Dr. Viera Lukacova Honored as Fellow by the American Association of Pharmaceutical Scientists (AAPS)](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Chief Science Officer Dr. Viera Lukacova Honored as Fellow by the American Association of Pharmaceutical Scientists (AAPS)
Dr. Lukacova’s outstanding contributions to pharmaceutical research and innovation to be recognized with seven others at AAPS PharmSci 360
![Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment
Elevated ALT levels during clinical trials led researchers to use quantitative systems toxicology (QST) software to better understand potential underlying mechanisms
![Simulations Plus Releases ADMET Predictor® 11](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Releases ADMET Predictor® 11
New functionality, models, and partner data power predictive accuracy from the industry-leading machine learning platform
![Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results
Total revenue of $16.2 million and diluted earnings per share (EPS) of $0.20
Maintains full-year revenue guidance of $59.3 - $62.0 million (+10-15%) and EPS guidance of $0.63 - $0.67
![Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities
Acquisition increases breadth and depth of QSP expertise and range of therapeutic applications
![Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of a new integrated pulmonary software and services package.
![Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
Provides FDA with software tools to investigate drug-induced liver injury in clinical trials
![Simulations Plus Reports Second Quarter Fiscal 2023 Financial Results](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Reports Second Quarter Fiscal 2023 Financial Results
Total revenue of $15.8 million; Diluted Earnings Per Share (EPS) of $0.20;
Maintains full-year revenue guidance of $59.3 - $62.0 million (+10-15%) and EPS Guidance of $0.63 - $0.67
![MIDD+ 2023 Panelists Discuss How to Increase Gender Equity for Women in Science](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
MIDD+ 2023 Panelists Discuss How to Increase Gender Equity for Women in Science
More than 150 people from around the world gathered virtually this past February for a panel discussion about how to move the needle on gender equity for women in science.
![Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology
Drug discovery services partnership with Sino-American Cancer Foundation focuses on the development of actionable hits against the MTHFD2 target
![Simulations Plus Sets Date for Second Quarter Fiscal Year 2023 Earnings Release and Conference Call](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Sets Date for Second Quarter Fiscal Year 2023 Earnings Release and Conference Call
Conference call to be on Wednesday, April 5, 2023, at 5 p.m. EDT
![Simulations Plus to Present at Sidoti March Small-Cap Conference](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus to Present at Sidoti March Small-Cap Conference
Simulations Plus to Present at Sidoti March Small-Cap Conference
![Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
Promising intellectual property resulting from the collaboration with Polish Academy of Sciences will be jointly owned for further development opportunities
![Lixoft Adds New Data Formatting and Reporting Modules to MonolixSuite(TM) in Version 2023R1](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Lixoft Adds New Data Formatting and Reporting Modules to MonolixSuite(TM) in Version 2023R1
Update includes enhanced PKanalix, Monolix, and Simulx modules
![Simulations Plus to Present at Oppenheimer 33rd Annual Healthcare Conference](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus to Present at Oppenheimer 33rd Annual Healthcare Conference
We announced that management will be presenting at Oppenheimer’s 33rd Annual Healthcare Conference taking place virtually from March 13-15, 2023.
![Simulations Plus to Present at Raymond James 44th Annual Institutional Investors Conference](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus to Present at Raymond James 44th Annual Institutional Investors Conference
Management will be presenting at the Raymond James & Associates’ 44th Annual Institutional Investors Conference, scheduled for March 5-8, 2023, at the JW Marriott Grande Lakes in Orlando, Florida.
![Simulations Plus and Global Agrochemicals Leader to Collaborate on Machine Learning Models](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus and Global Agrochemicals Leader to Collaborate on Machine Learning Models
Data sharing partnership will expand chemical coverage space and improve model performance in support of new approach methodologies to ensure product safety
![Simulations Plus Releases Redesigned NAFLDsym® QSP Software Tool](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Releases Redesigned NAFLDsym® QSP Software Tool
NAFLDsym v2B Beta represents the first release in the faster, sleeker Julia infrastructure